Exact Mass: 585.2339
Exact Mass Matches: 585.2339
Found 388 metabolites which its exact mass value is equals to given mass value 585.2339
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Montelukast
Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the bronchoconstriction otherwise caused by the leukotriene, and results in less inflammation. Because of its method of operation, it is not useful for the treatment of acute asthma attacks. Again because of its very specific locus of operation, it does not interact with other allergy medications such as theophylline. Montelukast is marketed in United States and many other countries by Merck & Co. with the brand name Singulair. It is available as oral tablets, chewable tablets, and oral granules. In India and other countries, it is also marketed under the brand name Montair®, produced by Indian company Cipla. R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03D - Other systemic drugs for obstructive airway diseases > R03DC - Leukotriene receptor antagonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D020024 - Leukotriene Antagonists D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists D065693 - Cytochrome P-450 Enzyme Inducers > D065694 - Cytochrome P-450 CYP1A2 Inducers COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Bluensomycin
C784 - Protein Synthesis Inhibitor > C2363 - Aminoglycoside Antibiotic C254 - Anti-Infective Agent > C258 - Antibiotic
Tigecycline
Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was given a U.S. Food and Drug Administration (FDA) fast-track approval and was approved on June 17, 2005. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01A - Tetracyclines > J01AA - Tetracyclines D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic Same as: D01079
fosamprenavir
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AE - Protease inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
Fosamprenavir
Fosamprenavir is only found in individuals that have used or taken this drug. It is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.Fosamprenavir is rapidly hydrolyzed to amprenavir by cellular phosphatases in the gut epithelium as it is absorbed. Amprenavir is an inhibitor of HIV-1 protease. During HIV replication, HIV protease cleaves viral polypeptide products of the Gag and Gag-Pol genes to form structural proteins of the virion core and essential viral enzymes. Amprenavir interferes with this process by binding to the active site of HIV-1 protease, thereby preventing the processing of viral Gag and Gag-Pol polyprotein precursors, resulting in the formation of immature non-infectious viral particles. J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AE - Protease inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
9-Ethyl-4,6,9,10,11-pentahydroxy-7-[(2R,4S,5S,6S)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-8,10-dihydro-7H-tetracene-5,12-dione
2-[1-[[[(1R)-1-[3-[2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]thio]methyl]cyclopropyl]acetic acid
Cadazolid
Isoflavone base + 1O, 2MeO, O-Hex+C7H12NO
Annotation level-3
Tyr Phe Glu Lys
Glu Phe Tyr Lys
Montelukast
R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03D - Other systemic drugs for obstructive airway diseases > R03DC - Leukotriene receptor antagonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D020024 - Leukotriene Antagonists D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists D065693 - Cytochrome P-450 Enzyme Inducers > D065694 - Cytochrome P-450 CYP1A2 Inducers COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; INTERNAL_ID 2745
Ala Phe Trp Tyr
Ala Phe Tyr Trp
Ala Trp Phe Tyr
Ala Trp Tyr Phe
Ala Tyr Phe Trp
Ala Tyr Trp Phe
Cys Asp Trp Tyr
Cys Asp Tyr Trp
Cys Phe Met Trp
Cys Phe Trp Met
Cys Met Phe Trp
Cys Met Trp Phe
Cys Trp Asp Tyr
Cys Trp Phe Met
Cys Trp Met Phe
Cys Trp Tyr Asp
Cys Tyr Asp Trp
Cys Tyr Trp Asp
Asp Cys Trp Tyr
Asp Cys Tyr Trp
Asp Glu His Trp
Asp Glu Trp His
Asp His Glu Trp
Asp His Trp Glu
Asp Trp Cys Tyr
Asp Trp Glu His
Asp Trp His Glu
Asp Trp Tyr Cys
Asp Tyr Cys Trp
Asp Tyr Trp Cys
Glu Asp His Trp
Glu Asp Trp His
Glu Phe Lys Tyr
Glu Phe Gln Tyr
Glu Phe Tyr Gln
Glu His Asp Trp
Glu His Trp Asp
Glu Lys Phe Tyr
Glu Lys Tyr Phe
Glu Gln Phe Tyr
Glu Gln Tyr Phe
Glu Trp Asp His
Glu Trp His Asp
Glu Tyr Phe Lys
Glu Tyr Phe Gln
Glu Tyr Lys Phe
Glu Tyr Gln Phe
Phe Ala Trp Tyr
Phe Ala Tyr Trp
Phe Cys Met Trp
Phe Cys Trp Met
Phe Glu Lys Tyr
Phe Glu Gln Tyr
Phe Glu Tyr Lys
Phe Glu Tyr Gln
Phe Phe Ser Trp
Phe Phe Trp Ser
Phe His Pro Trp
Phe His Trp Pro
Phe Lys Glu Tyr
Phe Lys Tyr Glu
Phe Met Cys Trp
Phe Met Trp Cys
Phe Pro His Trp
Phe Pro Trp His
Phe Gln Glu Tyr
Phe Gln Tyr Glu
Phe Ser Phe Trp
Phe Ser Trp Phe
Phe Trp Ala Tyr
Phe Trp Cys Met
Phe Trp Phe Ser
Phe Trp His Pro
Phe Trp Met Cys
Phe Trp Pro His
Phe Trp Ser Phe
Phe Trp Tyr Ala
Phe Tyr Ala Trp
Phe Tyr Glu Lys
Phe Tyr Glu Gln
Phe Tyr Lys Glu
Phe Tyr Gln Glu
Phe Tyr Trp Ala
His Asp Glu Trp
His Asp Trp Glu
His Glu Asp Trp
His Glu Trp Asp
His Phe Pro Trp
His Phe Trp Pro
His Ile Met Trp
His Ile Trp Met
His Leu Met Trp
His Leu Trp Met
His Met Ile Trp
His Met Leu Trp
His Met Trp Ile
His Met Trp Leu
His Pro Phe Trp
His Pro Trp Phe
His Trp Asp Glu
His Trp Glu Asp
His Trp Phe Pro
His Trp Ile Met
His Trp Leu Met
His Trp Met Ile
His Trp Met Leu
His Trp Pro Phe
Ile His Met Trp
Ile His Trp Met
Ile Met His Trp
Ile Met Trp His
Ile Gln Tyr Tyr
Ile Trp His Met
Ile Trp Met His
Ile Tyr Gln Tyr
Ile Tyr Tyr Gln
Lys Glu Phe Tyr
Lys Glu Tyr Phe
Lys Phe Glu Tyr
Lys Phe Tyr Glu
Lys Tyr Glu Phe
Lys Tyr Phe Glu
Leu His Met Trp
Leu His Trp Met
Leu Met His Trp
Leu Met Trp His
Leu Gln Tyr Tyr
Leu Trp His Met
Leu Trp Met His
Leu Tyr Gln Tyr
Leu Tyr Tyr Gln
Met Cys Phe Trp
Met Cys Trp Phe
Met Phe Cys Trp
Met Phe Trp Cys
Met His Ile Trp
Met His Leu Trp
Met His Trp Ile
Met His Trp Leu
Met Ile His Trp
Met Ile Trp His
Met Leu His Trp
Met Leu Trp His
Met Ser Trp Tyr
Met Ser Tyr Trp
Met Trp Cys Phe
Met Trp Phe Cys
Met Trp His Ile
Met Trp His Leu
Met Trp Ile His
Met Trp Leu His
Met Trp Ser Tyr
Met Trp Tyr Ser
Met Tyr Ser Trp
Met Tyr Trp Ser
Pro Phe His Trp
Pro Phe Trp His
Pro His Phe Trp
Pro His Trp Phe
Pro Trp Phe His
Pro Trp His Phe
Gln Glu Phe Tyr
Gln Glu Tyr Phe
Gln Phe Glu Tyr
Gln Phe Tyr Glu
Gln Ile Tyr Tyr
Gln Leu Tyr Tyr
Gln Tyr Glu Phe
Gln Tyr Phe Glu
Gln Tyr Ile Tyr
Gln Tyr Leu Tyr
Gln Tyr Tyr Ile
Gln Tyr Tyr Leu
Ser Phe Phe Trp
Ser Phe Trp Phe
Ser Met Trp Tyr
Ser Met Tyr Trp
Ser Trp Phe Phe
Ser Trp Met Tyr
Ser Trp Tyr Met
Ser Tyr Met Trp
Ser Tyr Trp Met
Trp Ala Phe Tyr
Trp Ala Tyr Phe
Trp Cys Asp Tyr
Trp Cys Phe Met
Trp Cys Met Phe
Trp Cys Tyr Asp
Trp Asp Cys Tyr
Trp Asp Glu His
Trp Asp His Glu
Trp Asp Tyr Cys
Trp Glu Asp His
Trp Glu His Asp
Trp Phe Ala Tyr
Trp Phe Cys Met
Trp Phe Phe Ser
Trp Phe His Pro
Trp Phe Met Cys
Trp Phe Pro His
Trp Phe Ser Phe
Trp Phe Tyr Ala
Trp His Asp Glu
Trp His Glu Asp
Trp His Phe Pro
Trp His Ile Met
Trp His Leu Met
Trp His Met Ile
Trp His Met Leu
Trp His Pro Phe
Trp Ile His Met
Trp Ile Met His
Trp Leu His Met
Trp Leu Met His
Trp Met Cys Phe
Trp Met Phe Cys
Trp Met His Ile
Trp Met His Leu
Trp Met Ile His
Trp Met Leu His
Trp Met Ser Tyr
Trp Met Tyr Ser
Trp Pro Phe His
Trp Pro His Phe
Trp Ser Phe Phe
Trp Ser Met Tyr
Trp Ser Tyr Met
Trp Tyr Ala Phe
Trp Tyr Cys Asp
Trp Tyr Asp Cys
Trp Tyr Phe Ala
Trp Tyr Met Ser
Trp Tyr Ser Met
Tyr Ala Phe Trp
Tyr Ala Trp Phe
Tyr Cys Asp Trp
Tyr Cys Trp Asp
Tyr Asp Cys Trp
Tyr Asp Trp Cys
Tyr Glu Phe Lys
Tyr Glu Phe Gln
Tyr Glu Lys Phe
Tyr Glu Gln Phe
Tyr Phe Ala Trp
Tyr Phe Glu Gln
Tyr Phe Lys Glu
Tyr Phe Gln Glu
Tyr Phe Trp Ala
Tyr Ile Gln Tyr
Tyr Ile Tyr Gln
Tyr Lys Glu Phe
Tyr Lys Phe Glu
Tyr Leu Gln Tyr
Tyr Leu Tyr Gln
Tyr Met Ser Trp
Tyr Met Trp Ser
Tyr Gln Glu Phe
Tyr Gln Phe Glu
Tyr Gln Ile Tyr
Tyr Gln Leu Tyr
Tyr Gln Tyr Ile
Tyr Gln Tyr Leu
Tyr Ser Met Trp
Tyr Ser Trp Met
Tyr Trp Ala Phe
Tyr Trp Cys Asp
Tyr Trp Asp Cys
Tyr Trp Phe Ala
Tyr Trp Met Ser
Tyr Trp Ser Met
Tyr Tyr Ile Gln
Tyr Tyr Leu Gln
Tyr Tyr Gln Ile
Tyr Tyr Gln Leu
1-[[[(4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,11,12a-pentahydroxy-6-methyl-1,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carbonyl]amino]methyl]piperidine-3-carboxylic acid
Fosinopril sodium
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
Cadazolid
D000890 - Anti-Infective Agents > D023303 - Oxazolidinones C254 - Anti-Infective Agent > C258 - Antibiotic
Titanium, tris(3-aminophenolato-.kappa.O)2,2-bis(2-propenyloxy-.kappa.O)methyl-1-butanolato-.kappa.O-, (OC-6-22)-
(1-{[(1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl)sulfanyl]methyl}cyclopropyl)acetic acid
5-[2-Acetylamino-2-(1-biphenyl-4-ylmethyl-2-oxo-azepan-3-ylcarbamoyl)-ethyl]-2-carboxymethyl-benzoic acid
Tigecycline
Tetracycline in which the hydroxy group at position 5 and the methyl group at position 6 are replaced by hydrogen, and with a dimethylamino substituent and an (N-tert-butylglycyl)amino substituent at positions 7 and 9, respectively. A glycylcycline antibiotic, it has activity against a broad range of Gram-positive and Gram-negative bacteria, including tetracycline-resistant organisms. It is used for the intravenous treatment of complicated skin and skin structure infections caused by susceptible organisms. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01A - Tetracyclines > J01AA - Tetracyclines D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic Same as: D01079
9-Ethyl-4,6,9,10,11-pentahydroxy-7-[(2R,4S,5S,6S)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-8,10-dihydro-7H-tetracene-5,12-dione
5-Methyl-tetrahydropteroyl-alpha-glutamylglutamate
[4-O-[4-O-(beta-D-Mannopyranosyl)-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl]-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl]amine
(2R)-3-(3-chloro-4-hydroxyphenyl)-2-[[(E,3R,8S,9S,10R)-2-ethoxy-3,9-dihydroxy-4-methoxy-6,8,10-trimethyl-7-oxotetradec-5-enoyl]amino]propanoic acid
(2S)-2-[[(4S)-4-[[4-[(6aR)-3-amino-1-oxo-5,6,6a,7-tetrahydro-2H-imidazo[1,5-f]pteridin-10-ium-8-yl]benzoyl]amino]-4-carboxybutanoyl]amino]pentanedioic acid
(3S)-3-[(2S)-2-(Z-Val-Leu-Amino)-3-(2-thiazolyl)-3-oxopropyl]-2-pyrrolizinone
(4S,4aS,5aR,12aS)-9-[[2-(tert-butylamino)-1-oxoethyl]amino]-4,7-bis(dimethylamino)-10,12a-dihydroxy-1,3,11,12-tetraoxo-4,4a,5,5a,6,11a-hexahydrotetracene-2-carboxamide
2-(2,4-dimethoxyphenyl)-N-{4-methoxy-3-[(2,2,3,3-tetrafluoropropoxy)methyl]benzylidene}-4-quinolinecarbohydrazide
1,2-dioctanoyl-sn-glycero-3-phospho-1D-myo-inositol(1-)
A 1-phosphatidyl-1D-myo-inositol(1-) that is the conjugate base of 1,2-dioctanoyl-sn-glycero-3-phospho-1D-myo-inositol, obtained by deprotonation of the phosphate OH group; major species at pH 7.3.